Market research
INNT 9 Meters Biopharma, Inc
NASDAQ USD Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- -0.54
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Not available
- Industry
- Not available
- ISIN
- US6544051096
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- -0.54
About
About 9 Meters Biopharma, Inc
9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the INNT discussion.
5 years, 4 months ago
9 Meters Biopharma, Inc is currently in a long term uptrend where the price is trading 20.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Based on the above factors, 9 Meters Biopharma, Inc gets an overall score of 2/5.